Moberg Derma AB (OMX: MOB) has analysed data from approximately fifty per cent of the patients in the ongoing open phase II study for MOB-015. Based on the analysis, the company assesses that there is low probability that the final results from the study will be sufficient for out-licensing the project. Further studies will probably be required before continuing to phase III. The ongoing phase II study will be completed and results are expected by the end of the year.